The thorough QT study: Let's be precise

Cardiology Journal

Volumn 18, Issue 4, 2011, Pages 341-342

  Wedam, Erich F ^a   Haigney, Mark C ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETOCONAZOLE; MOXIFLOXACIN; PENTAMIDINE; RANOLAZINE; TERFENADINE; VERAPAMIL;

CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG COST; DRUG MECHANISM; EDITORIAL; ETHER A GO GO RELATED GENE; GENE; HEART OUTPUT MEASUREMENT; HEART REPOLARIZATION; HUMAN; QT INTERVAL; QT PROLONGATION; SYNCOPE; T WAVE; TORSADE DES POINTES;

AZA COMPOUNDS; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; MALE; QUINOLINES; SIGNAL PROCESSING, COMPUTER-ASSISTED;

EID: 79960568270     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use. JAMA, 1990; 264: 2788-2790.
2. http://www.ema.europa.eu/docs/en_GB/document_library//Scientific_guideline/2009/09/WC500002879.pdf.
3. http://www.fda.gov/downloads/RegulatoryInformation/Guidances//ucm129357.pdf.
4. Dennis A, Wang L, Wan X, Ficker E. HERG channel trafficking: Novel targets in drug-induced long QT syndrome. Biochem Soc Trans, 2007; 35 (Part 5): 1060-1063.
5. Cubeddu LX. Iatrogenic QT abnormalities and fatal arrhythmias: Mechanisms and clinical significance. Curr Cardiol Rev, 2009; 5: 166-176.
6. Shah RR, Drugs, QT. Interval prolongation and ICH E14: The need to get it right. Drug Saf, 2005; 28: 115-125.
7. Malik M, Garnett CE, Zhang J. Thorough QT studies: Questions and quandaries. Drug Saf, 2010; 33: 1-14.
8. Morganroth J, Lepor H, Hill LA, Volinn W, Hoel G. Effects of the selective alpha-1 adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, doubleblind, placebo and moxifloxa-cin controlled study. Clin Pharmacol Ther, 2010; 87: 609-613.
9. Darpo B, Fossa AA, Couderc JP et al. Improving the precision of QT measurements. Cardiol J, 2011; 18: 4010-410.
10. Malik M, Hnatkova K, Batchvarov V, Gang Y, Smetana P, Camm AJ. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation. Pacing Clin Electrophysiol, 2004; 27: 1659-1669.
11. Hondeghem LM. Thorough QT/QTc not so thorough: Removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electro-physiol, 2006; 17: 337-340.
12. Thomsen MB, Verduyn SC, Stengl M et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation, 2004; 110: 2453-2459.
13. Hinterseer M, Thomsen MB, Beckmann BM et al. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: A case control pilot study. Eur Heart J, 2008; 29: 185-190.
14. Couderc JP, Xia X, Peterson DR et al. T-wave morphology abnormalities in benign, potent, and arrhythmogenic I(kr) inhibition. Heart Rhythm, 2011 [Epub ahead of print].